I think there are two potential "suitors"-Merck makes keytruda which is being used in non-muscular invasive bladder cancer-once vicinium is approved the use of keytruda for this application will decrease and Merck will likely need to try and make up for this loss of revenue-the other potential suitor could be Astra Zeneca-they are using vicinium with a checkpoint inhibitor in a head and neck trial (the results to date have been "promising")---vicinium may also have a role in other applications-including as a radiologic agent to determine if tumor margins are clear after surgery
News 
Market Data 
Discover 
